Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319063759> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W4319063759 endingPage "9174" @default.
- W4319063759 startingPage "9167" @default.
- W4319063759 abstract "Abstract Background Hepatic failure induced by immune checkpoint inhibitors (ICIs) has been reported in only a few case series and case reports. Objective We aimed to explore the association between ICIs and hepatic failure and characterize the clinical features of ICI‐associated hepatic failure in the pharmacovigilance database. Methods Data from the first quarter (Q1) of 2015 to the fourth quarter (Q4) of 2021 in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database were retrieved for disproportionality and Bayesian analysis. Reporting odds ratios (ROR) and information component (IC) were used to evaluate correlations between ICIs and hepatic failure. Results Hepatic failure occurred in 0.19% (18,454/9,647,655) of all cases in the FAERS database, of which 654 cases were associated with ICIs. The overall median time from ICIs initiation to hepatic failure onset was 38 days, 72.3% of the adverse events occurred within the first 3 months, and 68.65% of the cases died after developing hepatic failure. In general, a strong signal was shown between ICIs and hepatic failure (ROR 025 = 2.70, IC 025 = 1.39). For the three categories of ICIs, programmed cell death 1 ligand 1 inhibitors (ROR 025 = 3.09, IC 025 = 1.57) had a higher risk signal than programmed cell death protein 1 inhibitors and cytotoxic T lymphocyte‐associated protein 4 inhibitors. For monotherapy, atezolizumab showed the strongest risk signal (ROR 025 = 4.07, IC 025 = 1.90). The combination of nivolumab and ipilimumab showed stronger signals of hepatic failure compared with nivolumab or ipilimumab alone (nivolumab + ipilimumab vs. ipilimumab: ROR 025 = 1.40, IC 025 = 0.16; nivolumab + ipilimumab vs. nivolumab: ROR 025 = 1.24, IC 025 = 0.34). Considering the concomitant agents used with ICIs, the majority of these regimens showed stronger signals than ICI monotherapy, such as acetaminophen (ICIs + acetaminophen vs. ICIs: ROR 025 = 1.06, IC 025 = 0.32). Conclusions ICIs had possible strong signals associated with hepatic failure, and most cases of hepatic failure occurred within the first 3 months and had poor outcomes, which should attract clinical attention." @default.
- W4319063759 created "2023-02-04" @default.
- W4319063759 creator A5014572481 @default.
- W4319063759 creator A5028385640 @default.
- W4319063759 creator A5035332982 @default.
- W4319063759 creator A5075736599 @default.
- W4319063759 creator A5077328321 @default.
- W4319063759 creator A5090094940 @default.
- W4319063759 date "2023-02-03" @default.
- W4319063759 modified "2023-10-02" @default.
- W4319063759 title "Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database" @default.
- W4319063759 cites W2064716383 @default.
- W4319063759 cites W2070159306 @default.
- W4319063759 cites W2147598330 @default.
- W4319063759 cites W2592692971 @default.
- W4319063759 cites W2788726176 @default.
- W4319063759 cites W2891486030 @default.
- W4319063759 cites W2899413762 @default.
- W4319063759 cites W2900174742 @default.
- W4319063759 cites W2945590213 @default.
- W4319063759 cites W2946950110 @default.
- W4319063759 cites W2964607730 @default.
- W4319063759 cites W2978198382 @default.
- W4319063759 cites W2992183033 @default.
- W4319063759 cites W3011161235 @default.
- W4319063759 cites W3111270650 @default.
- W4319063759 cites W3126732371 @default.
- W4319063759 cites W3134648386 @default.
- W4319063759 cites W3136244698 @default.
- W4319063759 cites W3150351010 @default.
- W4319063759 cites W3159932777 @default.
- W4319063759 cites W3165149874 @default.
- W4319063759 cites W3207128841 @default.
- W4319063759 cites W4206362366 @default.
- W4319063759 cites W4220682032 @default.
- W4319063759 cites W4226192741 @default.
- W4319063759 cites W4303684453 @default.
- W4319063759 cites W4319063759 @default.
- W4319063759 doi "https://doi.org/10.1002/cam4.5655" @default.
- W4319063759 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36734333" @default.
- W4319063759 hasPublicationYear "2023" @default.
- W4319063759 type Work @default.
- W4319063759 citedByCount "3" @default.
- W4319063759 countsByYear W43190637592023 @default.
- W4319063759 crossrefType "journal-article" @default.
- W4319063759 hasAuthorship W4319063759A5014572481 @default.
- W4319063759 hasAuthorship W4319063759A5028385640 @default.
- W4319063759 hasAuthorship W4319063759A5035332982 @default.
- W4319063759 hasAuthorship W4319063759A5075736599 @default.
- W4319063759 hasAuthorship W4319063759A5077328321 @default.
- W4319063759 hasAuthorship W4319063759A5090094940 @default.
- W4319063759 hasConcept C121608353 @default.
- W4319063759 hasConcept C126322002 @default.
- W4319063759 hasConcept C156957248 @default.
- W4319063759 hasConcept C197934379 @default.
- W4319063759 hasConcept C2775949291 @default.
- W4319063759 hasConcept C2777105317 @default.
- W4319063759 hasConcept C2777701055 @default.
- W4319063759 hasConcept C2780030458 @default.
- W4319063759 hasConcept C2781433595 @default.
- W4319063759 hasConcept C41008148 @default.
- W4319063759 hasConcept C57658597 @default.
- W4319063759 hasConcept C71924100 @default.
- W4319063759 hasConcept C77088390 @default.
- W4319063759 hasConceptScore W4319063759C121608353 @default.
- W4319063759 hasConceptScore W4319063759C126322002 @default.
- W4319063759 hasConceptScore W4319063759C156957248 @default.
- W4319063759 hasConceptScore W4319063759C197934379 @default.
- W4319063759 hasConceptScore W4319063759C2775949291 @default.
- W4319063759 hasConceptScore W4319063759C2777105317 @default.
- W4319063759 hasConceptScore W4319063759C2777701055 @default.
- W4319063759 hasConceptScore W4319063759C2780030458 @default.
- W4319063759 hasConceptScore W4319063759C2781433595 @default.
- W4319063759 hasConceptScore W4319063759C41008148 @default.
- W4319063759 hasConceptScore W4319063759C57658597 @default.
- W4319063759 hasConceptScore W4319063759C71924100 @default.
- W4319063759 hasConceptScore W4319063759C77088390 @default.
- W4319063759 hasFunder F4320316364 @default.
- W4319063759 hasFunder F4320335843 @default.
- W4319063759 hasIssue "8" @default.
- W4319063759 hasLocation W43190637591 @default.
- W4319063759 hasLocation W43190637592 @default.
- W4319063759 hasOpenAccess W4319063759 @default.
- W4319063759 hasPrimaryLocation W43190637591 @default.
- W4319063759 hasRelatedWork W3012061428 @default.
- W4319063759 hasRelatedWork W3016822790 @default.
- W4319063759 hasRelatedWork W3103774939 @default.
- W4319063759 hasRelatedWork W3109431802 @default.
- W4319063759 hasRelatedWork W4283697218 @default.
- W4319063759 hasRelatedWork W4286561354 @default.
- W4319063759 hasRelatedWork W4310859953 @default.
- W4319063759 hasRelatedWork W4319063759 @default.
- W4319063759 hasRelatedWork W4385380346 @default.
- W4319063759 hasRelatedWork W4386392387 @default.
- W4319063759 hasVolume "12" @default.
- W4319063759 isParatext "false" @default.
- W4319063759 isRetracted "false" @default.
- W4319063759 workType "article" @default.